{
    "ticker": "XBIO",
    "name": "Xenetic Biosciences, Inc.",
    "description": "Xenetic Biosciences, Inc. is a biopharmaceutical company focused on the development of innovative and proprietary drug delivery systems and biologic drugs. Founded in 2003, Xenetic is dedicated to advancing the science of drug delivery to improve the efficacy and safety of therapeutic agents. The company specializes in utilizing its proprietary platforms, such as its PolyXen\u2122 technology, which enhances the pharmacokinetics and bioavailability of drugs, offering significant potential for the treatment of various diseases. Xenetic's pipeline includes a range of products aimed at addressing unmet medical needs, particularly in the fields of oncology and rare diseases. The company collaborates with leading pharmaceutical companies to develop novel therapies and has a commitment to expanding its research and development efforts. With a strong focus on innovation, Xenetic aims to bridge the gap between science and medicine, providing patients with more effective treatment options and improving healthcare outcomes. The company's mission is to leverage its unique technologies to transform the way medicines are delivered to patients, ultimately contributing to the advancement of healthcare globally.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Burlington, Massachusetts, USA",
    "founded": "2003",
    "website": "https://www.xeneticbio.com",
    "ceo": "Jeffrey L. Eisenberg",
    "social_media": {
        "twitter": "https://twitter.com/XeneticBio",
        "linkedin": "https://www.linkedin.com/company/xenetic-biosciences/"
    },
    "investor_relations": "https://www.xeneticbio.com/investors",
    "key_executives": [
        {
            "name": "Jeffrey L. Eisenberg",
            "position": "CEO"
        },
        {
            "name": "Scott E. Kahn",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Delivery Systems",
            "products": [
                "PolyXen\u2122 Technology",
                "Oncology Therapeutics"
            ]
        },
        {
            "category": "Biologics",
            "products": [
                "Rare Disease Treatments"
            ]
        }
    ],
    "seo": {
        "meta_title": "Xenetic Biosciences, Inc. | Innovative Drug Delivery Solutions",
        "meta_description": "Explore Xenetic Biosciences, Inc., a leader in innovative drug delivery systems and biologic therapies. Discover their commitment to advancing healthcare through cutting-edge technology.",
        "keywords": [
            "Xenetic Biosciences",
            "Biotechnology",
            "Pharmaceuticals",
            "Drug Delivery",
            "PolyXen",
            "Oncology",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Xenetic Biosciences known for?",
            "answer": "Xenetic Biosciences is known for its innovative drug delivery systems and biologic drugs aimed at improving therapeutic efficacy."
        },
        {
            "question": "Who is the CEO of Xenetic Biosciences?",
            "answer": "Jeffrey L. Eisenberg is the CEO of Xenetic Biosciences, Inc."
        },
        {
            "question": "Where is Xenetic Biosciences headquartered?",
            "answer": "Xenetic Biosciences is headquartered in Burlington, Massachusetts, USA."
        },
        {
            "question": "What technologies does Xenetic use?",
            "answer": "Xenetic utilizes its proprietary PolyXen\u2122 technology for drug delivery and has a focus on oncology and rare disease treatments."
        },
        {
            "question": "When was Xenetic Biosciences founded?",
            "answer": "Xenetic Biosciences was founded in 2003."
        }
    ],
    "competitors": [
        "ALNY",
        "EDIT",
        "CRSP",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "VRTX"
    ]
}